Maria Sklodowska-Curie Institute of Oncology

Warsaw 20-781

0 studies enrolling now · 4 studies all time

What they study most

Bladder Neoplasm, Carcinoma in Situ, Locally Advanced or Unresectable Metastatic Breast Cancer, Multiple Myeloma, Mycobacterium, Neoplasm Recurrence, Local, Relapsed Multiple Myeloma, Stage IV Breast Cancer, Transitional Cell, Carcinoma

Studies at this site

• Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy — Running, not enrolling
• Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma — Completed
• Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma — Completed
• Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer — Stopped early